149

CHAPTER 10

REFERENCES

1. Balasubramanian, D., Bansal, A. K., Basti, S., Bhatt, K. S., 1993, “Current

Ophthalmology. The Biology of Cataract. The Hyderabad Cataract Research

Group,” Indian Journal of Ophthalmology., 41, pp. 33-47.

2. Dobson, R., 2005, “Ozone Depletion Will Bring Big Rise in Number of

Cataracts,” British Medical Journal., 331(7528), pp. 1292.

3. WHO. Available Data on Blindness (update 1987) WHO/Pbl/87.14. WHO,

Geneva.

4. Foster, A., 2001, “Cataract and "Vision 2020-The Right to Sight" Initiative,”

British Journal of Ophthalmology., 85, pp. 635-639.

5. Minassian, D. C., Mehra V., 1990, “3.8 Million Blinded by Cataract Each Year.

Projections From the First Epidemiological Study of Incidence of Cataract

Blindness in India,” British Journal of Ophthalmology., 74, pp. 341-343.

6. Foster, A., 2000, “Vision 2020: The Cataract Challenge,” Community Eye Health.,

13, pp. 17-21.

7. Beebe, D., 2003, “The Lens: Adler's Physiology of the Eye,” 10th

Edition, A.A.

Kaufman Publications, St Louis, Mosby.

8. Bhat, S., 2001, “The Ocular Lens Epithelium,” Bioscience Reports., 21, pp. 537-

563.

9. Francis, P., Berry, V., Moore, A., Bhattacharya, S., 1999, “Lens Biology:

Development and Human Cataractogenesis,” Trends in Genetics., 15, pp. 191-196.

10. Bunce, G. E., 1994b, “Nutrition and Eye Disease of the Elderly,” Journal of

Nutritional Biochemistry., 5(1), pp. 66-77.

11. Spector, A., 1984, “The Search for a Solution to Senile Cataracts,” Investigative

Ophthalmology and Visual Sciences., 25(2), pp. 130-146.

12. Harrington, V., McCall, S., Huynh, S., Srivastava, K., Srivastava, O. P., 2004,

“Crystallins in Water Soluble-high Molecular Weight Protein Fractions and Water

150

Insoluble Protein Fractions in Aging and Cataractous Lenses,” Molecular Vision.,

10, pp. 476-489.

13. Marcantonio, J. M., Duncan, G., Rink, H., 1986, “Calcium-induced Opacification

and Loss of Protein in the Organ-cultured Bovine Lens,” Experimental Eye

Research., 42, pp. 617-630.

14. Sulochana, K. N., Punitham, R., Ramakrishnan, S., 2002, “Effect of Cigarette

Smoking on Cataract: Antioxidant Enzymes and Constituent Minerals in the Lens

and Blood of Humans,” Indian Journal of Pharmacology., 34, pp. 428-431.

15. Aksoy, H., Keles, S., Kocer, I., Akcay, F., 2001, “Diabetic Cataract and the Total

Antioxidant Status in Aqueous Humor,” Clinical Chemistry Laboratory Medicine.,

39, pp. 143-145.

16. Christine, Y., Paul, M., Robert, G. C., Panchapakesan, J., Elena, R., Angela, M.

H., 2002, “Hormone Replacement Therapy, Reproductive Factors, and the

Incidence of Cataract and Cataract Surgery: The Blue Mountains Eye Study,”

American Journal of Epidemiology., 155, pp. 997-1006.

17. Jaime, E. D., Dotzel, E., Abbot, F. L., 1997, “Steroid Induced Cataract: New

Perspectives from in vitro and Lens Culture Studies,” Experiment Eye Research.,

65, pp. 507-516.

18. Varma, S. D., Hegde, K. R., 2007, “Susceptibility of the Ocular Lens to Nitric

Oxide: Implications in Cataractogenesis,” Journal of Ocular Pharmacology and

Therapeutics., 23, pp. 188-195.

19. Harding, J., 1991, “Cataract: Biochemistry, Epidemiology and Pharmacology,”

Chapman-Hall, London, pp. 83-124.

20. Clark, J. I., 1994, “Development and Maintenance of Lens Transparency” In:

Albers, E. M., Jakobiec, F. A., editors. “Principles and Practice of

Ophthalmology,” W. B. Saunders, Philadelphia, pp. 114-123.

21. Ito, Y., Nabekura, T., Takeda, M., Nakao, M., Terao, M., Hori, R., 2001, “Nitric

Oxide Participates in Cataract Development in Selenite Treated rats,” Current Eye

Research., 22, pp. 215-220.

22. Monnier, V. M., Sell., D. R.., Nagaraj, R. H., Miyata, S., Grandhee, S., Odetti, P.,

1992, “Maillard Reaction-mediated Molecular Damage to Extracellular Matrix

and Other Tissue Proteins in Diabetes, Ageing and Uremia,” Diabetes., 41, pp. 36-

41.

151

23. Duhaiman, A. S., 1995, “Glycation of Human Lens Proteins from Diabetic and

Non-diabetic Senile Cataract Patients,” Glycoconjugate Journal., 12, pp. 618-621.

24. Sies, H., 1991, “Oxidative Stress II. Oxidants and Antioxidants,” Academic Press,

London.

25. Spector, A., 1995, “Oxidative Stress-induced Cataract: Mechanism of Action,”

FASEB., 9, pp. 1173-1182.

26. Slaughter, M. R., Thakkar, H., O'Brien, P. J., 2002, “Effect of Diquat on the

Antioxidant System and Cell Growth in Human Neuroblastoma Cells,”

Toxicology and Applied Pharmacology., 178(2), pp. 63-70.

27. Lou, M. F., 2003, “Redox Regulation in the Lens,” Progress in Retina and Eye

Research., 22(5), pp. 657-682.

28. Zigler, J. S., Bodaness, R. S., Gery, I., Kinoshita, J. H., 1983, “Effects of Lipid

Peroxidation Products on the Rat Lens in Organ Culture: A Possible Mechanism

of Cataract Initiation in Retinal Degenerative Disease,” Archives of Biochemistry

and Biophysics., 225(1), pp. 149-156.

29. Kleiman, N. J., Wang, R. R., Spector, A., 1990, “Hydrogen Peroxide-induced

DNA Damage in Bovine Lens Epithelial Cells,” Mutation Research., 240(1), pp.

35-45.

30. Cui, X. L., Lou, M. F., 1993, “The Effect and Recovery of Long-term H2O2

Exposure on Lens Morphology and Biochemistry,” Experimental Eye Research.,

57(2), pp. 157-167.

31. Mates, J. M., Sanchez-Jimenez, F., 1999, “Antioxidant Enzymes and Their

Implications in Pathophysiologic Processes,” Frontier Bioscience., 4, pp. D339-

345.

32. Altomare, E., Vendemiale, G., Grattagliano, I., Angelini, P., Micelli-Ferrari, T.,

Cardia, L., 1995, “Human Diabetic Cataract: Role of Lipid Peroxidation,”

Diabetes Metabolism., 21(3), pp. 173-179.

33. Spector, A., 2000, “Review: Oxidative Stress and Disease,” Journal of Ocular

Pharmacology and Therapeutics., 16(2), pp. 193-201.

34. Zigman, S., 2000, “Lens UVA Photobiology,” Journal of Ocular Pharmacology

and Therapeutics., 16(2), pp. 161-165.

152

35. Sanderson, J., Mclauchlan, W. R., Williamson, G., 1999, “Quercetin Inhibits

Hydrogen Peroxide-induced Oxidation of the Rat Lens,” Free Radical Biology and

Medicine., 26, pp. 639-645.

36. Slaughter, M. R., Thakkar, H., O'Brien, P. J., 2003, “Differential Expression of the

Lenticular Antioxidant System in Laboratory Animals: A Determinant of Species

Predilection to Oxidative Stress-induced Ocular Toxicity,” Current Eye Research.,

26, pp. 15-23.

37. Srikanthan, D., Bateman, O. A., Purkiss, A. G., Slingsby, C., 2004, “Sulfur in

Human Crystallins,” Experimental Eye Research., 79, pp. 823-831.

38. Halliwell, B., Gutteridge, J. M. C., 1999, “Free Radicals in Biology and

Medicine,” Oxford University Press Inc, New York.

39. Garner, M. H., Spector, A., 1980, “Selective Oxidation of Cysteine and

Methionine in Normal and Senile Cataractous Lenses,” Proceedings of the

National Academy of Sciences of the United States of America., 77, pp. 1274-

1277.

40. Truscott, R. J., Augusteyn, R. C., 1977, “Oxidative Changes in Human Lens

Proteins During Senile Nuclear Cataract Formation,” Biochimica et Biophysica

Acta., 492, pp. 43-52.

41. Truscott, R. J., 2005, “Age-related Nuclear Cataract: Oxidation is the Key,”

Experimental Eye Research., 80, pp. 709-725.

42. Taylor, A., Davies, K. J., 1987, “Protein Oxidation and Loss of Protease Activity

may lead to Cataract Formation in the Aged Lens,” Free Radical Biology and

Medicine., 3, pp. 371-377.

43. Davies, M. J., Truscott, R. J., 2001, “Photo-oxidation of Proteins and its role in

Cataractogenesis,” Journal of Photochemistry and Photobiology B., 63, pp. 114-

125.

44. Anderson, M. E., 1985, “Determination of Glutathione and Glutathione Disulfide

in Biological Samples,” Methods in Enzymology., 113: 548-555.

45. Meister, A., 1983, “Selective Modification of Glutathione Metabolism,” Science.,

220, pp. 472-477.

46. Tarwadi, K., Agte, V., 2004, “Linkage of Antioxidant, Micronutrient, and

Socioeconomic Status with the Degree of Oxidative Stress and Lens Opacity in

Indian Cataract Patients,” Nutrition., 20, pp. 261-267.

153

47. Roberts, J. E., 2001, “Ocular Phototoxicity,” Journal of Photochemistry and

Photobiology B: Biology., 64, pp. 136-143.

48. Blondin, J., Baragi, V., Schwartz, E., Sadowski, J. A., Taylor, A., 1986, “Delay of

UV-induced Eye Lens Protein Damage in Guinea Pigs by Dietary Ascorbate,”

Journal of Free Radical Biology and Medicine., 2, pp. 275-281.

49. Reddan, J. R., Sevilla, M. D., Giblin, F. J., Padgaonkar, V., Dziedzic, D. C.,

Leverenz, V., Misra, I. C., Peters, J. L., 1993, “The Superoxide Dismutase Mimic

TEMPOL Protects Cultured Rabbit Lens Epithelial Cells from Hydrogen Peroxide

Insult,” Experimental Eye Research., 56, pp. 543-554.

50. Spector, A., Kleiman, N. J., Huang, R. R., Wang, R. R., 1989, “Repair of H2O2-

induced DNA Damage in Bovine Lens Epithelial Cell Cultures,” Experimental

Eye Research., 49, pp. 685-698.

51. Shang, F., Gong, X., Taylor, A., 1997, “Activity of Ubiquitin-dependent Pathway

in Response to Oxidative Stress,” The Journal of Biological Chemistry., 272, pp.

23086-23093.

52. Andley, U. P., Rhim, J. S., Chylack Jr, L. T., Fleming, T. P., 1994, “Propagation

and Immortalization of Human Lens Epithelial Cells in Culture,” Investigative

Ophthalmology and Visual Sciences., 35, pp. 3094-3102.

53. Ahuja, R. P., Borchman, D., Dean, W. L., Paterson, C. A., Zeng, J., Zhang, Z.,

Ferguson- Yankey, S., Yappert, M. C., 1999, “Effect of Oxidation on Ca2+

-

ATPase Activity and Membrane Lipids in Lens Epithelial Microsomes,” Free

Radical Biology and Medicine., 27, pp. 177-185.

54. Babizhayev, M. A., Deyev, A. I., Linberg, L. F., 1988, “Lipid Peroxidation as a

Possible Cause of Cataract,” Mechanisms of Ageing and Development., 44, pp.

69-89.

55. Jedziniak, J. A., Kinoshita, J. H., Yates, E. M., Hocker, L. O., Benedek, G. B.,

1972, “Calcium Induced Aggregation of Bovine Lens alpha Crystallins,”

Investigative Ophthalmology and Visual Sciences., 11, pp. 905-915.

56. Delamere, N. A., Paterson, C. A., Borchman, D., Manning, R. E., 1993, “The

Influence of Calcium on the Rabbit Lens Sodium Pump,” Investigative

Ophthalmology and Visual Sciences., 34, pp. 405-412.

57. Hightower, K. R., Duncan, G., Harrison, S. E., 1985, “Intracellular Calcium

Concentration and Calcium Transport in the Rabbit Lens,” Investigative

Ophthalmology and Visual Sciences., 26, pp. 1032-1034.

154

58. Tamada, Y., Fukiage, C., Nakamura, Y., Azyma, M., Kim, Y. H., Shearer, T. R.,

2000, “Evidence for Apoptosis in the Selenite Rat Model of Cataract,”

Biochemical and Biophysical Research Communications., 275, pp. 300-306.

59. Zigler, J. S., Qin, C., Kamiya, T., Krishna, M. C., Cheng, Q. F., Tumminia, S.,

Russell, P., 2003, “Tempol-H Inhibits Opacification of Lenses in Organ Culture,”

Free Radical Biology and Medicine., 35, pp. 1194-1202.

60. Obin, M., Shang, F., Gong, X., Handelman, G., Blumberg, J., Taylor, A., 1998,

“Redox Regulation of Ubiquitin-conjugating Enzymes: Mechanistic Insights

Using the Thiol Specific Oxidant Diamide,” FASEB Journal., 12, pp. 561-569.

61. Lou, M. F., Dickerson, J. E., Jr., Garadi, R., 1990, “The Role of Protein-thiol

Mixed Disulfides in Cataractogenesis,” Experimental Eye Research., 50, pp. 819-

826.

62. Zenon, G. J., Abobo, C. V., Carter, B. L., Ball, D. W., 1990, “Potential Use of

Aldose Reductase Inhibitors to Prevent Diabetic Complications,” Clinical

Pharmacy., 9, pp. 446-457.

63. Nakai, N., Fujii, Y., Kobashi, K., Nomura, K., 1985, “Aldose Reductase

Inhibitors: Flavonoids, Alkaloids, Acetophenones, Benzophenones, and

Spirohydantoins of Chroman,” Archives of Biochemistry and Biophysics., 239,

pp. 491-496.

64. Varma, S. D., Mikuni, I., Kinoshita J. H., 1975, “Flavonoids as Inhibitors of Lens

Aldose Reductase,” Science., 188, pp. 1215-1216.

65. Mohan, M., Gupta, S. K., Agnihotri, S., Joshi, S., Uppal, R. K., 1988,

“Anticataract Action of Topical Quercetin and Myricetin in Galactosemic Rats,”

Medical Science Research., 16, pp. 685-686.

66. Kathleen, N. D., 2001, “Natural Therapies for Ocular Disorders: Cataracts and

Glaucoma,” Alternative Medicine Review., 6, pp. 141-166.

67. Sanghyun, L., Sang, H. S., Kim, J. S., Shin, K. H., Kang, S. S., 2005, “Aldose

Reductase Inhibitors from the Fruiting Bodies of Ganoderma applanatum,”

Biological and Pharmaceutical Bulletin., 28, pp. 1103-1105.

68. Varma, S. D., Hegde, K. R., 2005, “Prevention of Cataract by Pyruvate in

Experimentally Diabetic Mice,” Molecular Cell Biochemistry., 269, pp. 115-120.

69. Suryanarayana, P., Kumar, A. P., Saraswat, M., Mark, P., Reddy, G. B., 2004,

“Inhibition of Aldose Reductase by Tannoid Principles of Emblica officinalis:

155

Implications for the Prevention of Sugar Cataract,” Molecular Vision., 10, pp.

148-154.

70. Yokoyama, T., Sasake, H., Giblin, F. J., Reddy V. N., 1994, “A Physiological

Level of Ascorbate Inhibits Galactose Cataracts in Guinea Pigs by Decreasing

Polyol Accumulation in the Lens Epithelium: A Dehydro Ascorbate Linked

Mechanism,” Experimental Eye Research., 58, pp. 207-218.

71. Cunningham, J. J., Mearkle, P. L., Brown, R. G., 1994, “Vitamin C: An Aldose

Reductase Inhibitor that Normalizes Erythrocyte Sorbitol in Insulin Dependent

Diabetes Mellitus,” Journal of the American College of Nutrition., 13, pp. 344-

350.

72. Moghaddam, M. S., Kumar, P. A., Reddy, G. B., Ghole, V. S., 2005, “Effect of

Diabecon on Sugar-induced Lens Opacity in Organ Culture: Mechanism of

Action,” Journal of Ethnopharmacology., 97, pp. 397-403.

73. Egerton, M., Harding, R. S., 1989, “Protection Against Cataract by Aspirin,

Paracetamol, and Ibuprofen,” Acta Ophthalmologica., 67, pp. 518-524.

74. Gupta, S. K., Joshi, S., 1991, “Naproxen: An Aldose Reductase Inhibitor and

Potential Anti-cataract Agent,” Developments in Ophthalmology., 21, pp. 171-

178.

75. Gupta, S. K., Joshi, S., 1994, “Role of Naproxen as Antioxidant in Selenite

Cataract,” Ophthalmic Research., 26, pp. 226-231.

76. Gupta, S. K., Joshi, S., 1993, “Prevention of Photo Peroxidation of Lens Lipids by

Naproxen,” Afro Asian Journal of Ophthalmology., 12, pp. 295-297.

77. Gupta, S. K., Agnihotri, S., Joshi, S., 1989, “Anti-cataract Action of Topical

Sulindac in Galactosemic Rats,” Afro Asian Journal of Ophthalmology., 8, pp. 57-

61.

78. Varma, S. D., Hegde, K. R., 2004, “Effect of α-ketoglutarate Against Selenite

Cataract Formation,” Experimental Eye Research., 79, pp. 913-918.

79. Gupta, S. K., Mohanty, I., Joshi, S., Trivedi, D., Srivastava, S., 2002, “Lycopene

Prevents Sugar-induced Morphological Changes and Modulates Antioxidant

Status of Human Lens Epithelial Cells,” British Journal of Nutrition., 88, pp. 347-

354.

80. Ayala, M. N., Soderberg, P. G., 2004, “Vitamin C can Protect Against Ultraviolet

Radiation Induced Cataract in Albino Rats,” Ophthalmic Research., 36, pp. 264-

269.

156

81. Abe, M., Reiter, R. J., Orhii, P. B., Hara, M., Poeggeler, B., 1994, “Inhibitory

Effect of Melatonin on Cataract Formation in Newborn Rats: Evidence for an

Antioxidative Role for Melatonin,” Journal of Pineal Research., 17, pp. 94-100.

82. Hockwin, O., Weigelin, E., Baur, M., Boutros G., 1982, “Kontrollietre Klinische

Studie Uber Die Wirksankeit Von Phaken als Anti-kataract Medicament,”

Fortschritte der Ophthalmologie., 79, pp. 179-183.

83. David, L. W., 2006, “Oxidation, Antioxidants and Cataract Formation: A

Literature Review,” Veterinary Ophthalmology., 9, pp. 292-298.

84. Ohta, Y., Niwa, T., Yamasaki, T., 2001, “Effect of Prolonged Marginal Ascorbic

Acid Deficiency on Lenticular Levels of Antioxidants and Lipid Peroxide in

Guinea Pig,” International Journal of Vitamin and Nutritional Research., 71, pp.

103-109.

85. Saxena, P., Saxena, A. K., Monnier, V. M., 1996, “High Galactose Levels in vitro

and in vivo Impair Ascorbate Regeneration and Increase Ascorbate-mediated

Glycation in Cultured Rat Lens,” Experimental Eye Research., 63, pp. 535-545.

86. Mody, V. C., Kakar, M., Elfving, A., Soderberg, P. G., Lofgren, S., 2005,

“Ascorbate in the Rat Lens: Dependence on Dietary Intake,” Ophthalmic

Research., 37, pp. 142-149.

87. Labgle, U. W., Wolf, A., Cordier, A., 1997, “Enhancement of SDZ ICT 322-

induced Cataracts and Skin Changes in Rats following Vitamin E and Selenium

Deficient Diet,” Archives of Toxicology., 71, pp. 283-289.

88. Kojima, M., Shui, Y. B., Murano, M., Nagata, O., Hockwin, K., Sasaki, K., 2002,

“Low Vitamin E Level as a Subliminal Risk Factor in a Rat Model of Predisolone-

induced Cataract,” Investigative Ophthalmology and Visual Sciences., 43, pp.

1116-1120.

89. Reddy, G. B., Nayak, S., Reddy, P. Y., Seetharam, K., 2001, “Reduced Levels of

Rat Lens Antioxidant Vitamins Upon in vitro UVB Irradiation,” Journal of

Nutrition Biochemistry., 12, pp. 121-124.

90. Horwitz, J., Dovrat, A., Straatsma, B. E., Revilla, P. J., Lightfoot, D. O., 1987,

“Glutathione Reductase in Human Lens Epithelium: FAD-induced in vitro

Activation,” Current Eye Research., 6, pp. 1249-1256.

91. Bhat, K. S., 1987, “Nutritional Status of Thiamine, Riboflavin and Pyridoxine in

Cataract Patients,” Nutrition Reports International., 36, pp. 685-692.

157

92. Karakucuk, S., Ertugrul Mirza, G., Faruk Ekinciler, O., Saraymen, R., Karakucuk,

I., Ustdal, M., 1995, “Selenium Concentrations in Serum, Lens and Aqueous

Humor of Patients with Senile Cataract,” Acta Ophthalmologica., 73, pp. 329-332.

93. Cumming, R. G., Mitchell, P., Smith, W., 2000, “Diet and Cataract: The Blue

Mountains Eye Studies,” Ophthalmology., 107, pp. 450-456.

94. Mares-Perlman, J. A., Brady, W. E., Klein, B. E., Klein, R., Haus, G. J., Palta, M.,

1995, “Diet and Nuclear Lens Opacities,” Americal Journal of Epidemiology., 41,

pp. 322-334.

95. Clinton, S. K., 1998, “Lycopene: Chemistry, Biology and Implications for Human

Health and Disease,” Nutrition Review., 56, pp. 35-51.

96. Gupta, S. K., Trivedi, D., Srivastava, S., Joshi, S., Halder, N., Varma S. D., 2003,

“Lycopene Attenuates Oxidative Stress Induced Experimental Cataract

Development: An in vitro and in vivo Study,” Nutrition., 19, pp. 794-799.

97. Rao, K. E., 1990, “Oxygen Radical Scavenging Activity of Curcumin,”

International Journal of Pharmacology., 58, pp. 237-240.

98. Suryanarayana, P., Krishnaswamy, K., Reddy, G. B., 2003, “Effect of Curcumin

on Galactose-induced Cataractogenesis in Rat,” Molecular Vision., 9, pp. 223-

230.

99. Suryanaraya, P., Saraswat, M., Mrudula, T., Krishna, T. P., Krishnaswamy, K.,

Reddy, G. B., 2005, “Curcumin and Turmeric Delay Streptozotocin Induced

Diabetic Cataract in Rats,” Investigative Ophthalmology and Visual Sciences., 46,

pp. 2092-2099.

100. Padmaja, S., Raju, T. N., 2004, “Antioxidant Effect of Curcumin in Selenium

Induced Cataract of Wistar Rats,” Indian Journal of Experimental Biology., 42, pp.

601-603.

101. Horakova, L., Stolc, S., 1998, “Antioxidant and Pharmacodynamic Effects of

Pyridoindole Stobadine,” General Pharmacology., 30, pp. 627-638.

102. Stefek, M., Krizanova, L., Trnkova, Z., 1999, “Oxidative Modification of Serum

Albumin in an Experimental Glycation Model of Diabetes Mellitus in vitro: Effect

of the Pyridoindole Antioxidant Stobadine,” Life Sciences., 65, pp. 1995-1997.

103. Kyselova, Z., Gajdosik, A., Gajdosikova, A., Uliena, O., Mihalova, D., Karasu, C.,

2005, “Effect of the Pyridoindole Antioxidant Stobadine on Development of

Experimental Diabetic Cataract and on Lens Protein Oxidation in Rats:

Comparison with Vitamin E and BHT,” Molecular Vision., 11, pp. 56-65.

158

104. Gupta, S. K., Srivastava, S., Trivedi, D., Joshi, S., Nabanita, H., 2005, “Ocimum

sanctum Modulates Selenite-induced Cataractogenic Changes and Prevents Rat

Lens Opacification,” Current Eye Research., 30, pp. 583-591.

105. Vats, V., Yadav, S. P., Biswas, N. R., Grover, J. K., 2004, “Anti-cataract Activity

of Pterocarpus marsupium bark and Trigonella foenum Seeds Extract in Alloxan

Diabetic Rats,” Journal of Ethnopharmacology., 93, pp. 289-294.

106. Durukan, A. H., Evereklioglu, C., Hurmeric, V., Kerimoglu, H., Erdurman, C.,

Bayraktar, M. Z., 2006, “Ingestion of IH636 Grape Seed Proanthocyanidin Extract

to Prevent Selenite-induced Oxidative Stress in Experimental Cataract,” Journal of

Cataract and Refractive Surgery., 32, pp. 1041-1045.

107. Lija, Y., Biju, P. G., Reeni, A., Cibin, T. R., Sahasranamam, V., Abraham, A.,

2006, “Modulation of Selenite Cataract by the Flavonoid Fraction of Emilia

sonchifolia in Experimental Animal Models,” Phytotherapy Research., 20, pp.

1092-1095.

108. Biju, P. G., Devi, V. G., Lija, Y., Abraham, A., 2007, “Protection Against Selenite

Cataract in Rat Lens by Drevogenin D: A Triterpenoid Aglycone from Dregea

volubilis,” Journal of Medicinal Food., 10, pp. 308-315.

109. Bravetti, G., 1989, “Preventive Medical Treatment of Senile Cataract with Vitamin

E and Anthocyanosides: Clinical Evaluation,” Annali de Ottalmologia e Clinica

Oculistica., 115, pp. 109.

110. Ertekin, M. V., Kocccer, I., Karslioglu, I., Taysi, S., Gepdiremen, A., Sezen O.,

2004, “Effects of Oral Ginkgo biloba Supplementation on Cataract Formation and

Oxidative Stress Occurring in Lenses of Rats Exposed to Total Cranium

Radiotherapy,” Japanese Journal of Ophthalmology., 48, pp. 499-502.

111. Gupta, S. K., Halder, N., Srivastava, S., Trivedi, D., Joshi, S., Varma, S. D., 2002,

“Green Tea (Camellia sinensis) Protects Against Selenite-induced Oxidative

Stress in Experimental Cataractogenesis,” Ophthalmic Research., 34, pp. 258-263.

112. Thiagarajan, G., Chandani, S., Sundari, C. S., Rao, S. H., Kulkarni, A. V.,

Balasubramanian, D., 2001, “An Oxidative Property of Green Tea and Black Tea

and Their Potential Ability to Retard the Progression of Eye Lens Cataract,”

Experimental Eye Research., 73, pp. 393-401.

113. Joe, A. V., Juan, Z., 2005, “Black and Green Tea Equally Inhibit Diabetic

Cataracts in a Streptozotocin-induced Rat Model of Diabetes,” Journal of

Agriculture Food Chemistry., 53, pp. 3710-3713.

159

114. Suryanarayana, P., Saraswat, J., Petrash, J. M., Reddy, G. B., 2007, “Emblica

officinalis and its Enriched Tannoids Delay Streptozotocin Induced Diabetic

Cataract in Rats,” Molecular Vision., 13, pp. 291-297.

115. Velpandian, T., Mathur, P., Sengupta, S., Gupta, S. K., 1998, “Preventive Effect of

Chyavanprash Against Steroid Induced Cataract in the Developing Chick

Embryo,” Phytotherapy Research., 12, pp. 320-323.

116. Zhao, W., Devamanoharan, P. S., Varma, S. D., 2002, “Diabetes Induced

Biochemical Changes in Rat Lens: Attenuation of Cataractogenesis by Pyruvate,”

Diabetes Obstetrics and Metabolism., 2, pp. 165-174.

117. Varma, S. D., Ramachandran, S., Devamanoharan, P. S., Morris, S. M., Ali, A. H.,

1995, “Prevention of Oxidative Damage to Rat Lens in vitro by pyruvate: Possible

Attenuation in vivo,” Current Eye Research., 14, pp. 643-649.

118. Maitra, I., Serbinova, E., Trischier, H., Packer, L., 1995, “Alpha-lipoic Acid

Prevents Buthionine Sulfoximine Induced Cataract Formation in Newborn Rats,”

Free Radical Biology and Medicine., 18, pp. 823-829.

119. Hiraoka, T., Clark, J. I., Thurston, G. M., 1996, “Effect of Selected Anticataract

Agents of Opacification in the Selenite Cataract Model,” Experimental Eye

Research., 62, pp. 11-19.

120. Kuck, J. F., Kuck, K. D., 1988, “The Emory Mouse Cataract: The Effects of

Cataractogenesis of Alpha-tocopherol, Penicillamine, Triethylenetetramine and

Mercapto-propionylglycine,” Journal of Ocular Pharmacology., 4, pp. 243-251.

121. Wang, Z., Hess, J. L., Bunce, G. E., 1992, “Deferoxamine Effect on Selenite-

induced Cataract Formation in Rats,” Investigative Ophthalmology and Visual

Sciences., 33, pp. 2511-2519.

122. Jose, R., 1992, “Strength and Weakness of NPCB and Strategies for their

Evaluation” In: Khosla, P. K., editor. “Community Ophthalmology: An Indian

perspective,” Proceedings of First National Workshop on Community

Ophthalmology, New Delhi. All India Institute of Medical Sciences, New Delhi.,

pp. 79-85.

123. Govantes, C., Marin, J., 1996, “Effect of Angiotensin Converting Enzyme

Inhibitors on Quality of Life in Hypertensive Patients: Pharmacodynamic Basis,”

Fundamental Clinical Pharmacology., 10, pp. 400-405.

124. Ferrari, R., Cargnoni, A., Curello, S., Ceconi, C., Boraso, A., Visioli, O., 1992,

“Protection of Ischemic Myocardium by the Converting Enzyme Inhibitor

160

Zofenopril: Insight into its Mechanism of Action,” Journal of Cardiovascular

Pharmacology., 20, pp. 694-604.

125. Liu, T. H., Beckman, J. S., Freeman, B. A., Hogan, E. L., Hsu, C. Y., 1989,

“Polyethylene Glycol Conjugated Superoxide Dismutase and Catalase Reduce

Ischemic Brain Injury,” American Journal of Physiology., 256, pp. 589-593.

126. Kohara, K., Mikami, H., Okuda, N., Higaki, J., Ogihara, T., 1993, “Angiotensin

Blockade and the Progression of Renal Damage in the Spontaneously

Hypertensive Rat,” Hypertension., 21, pp. 975-979.

127. Kabour, A., Henegar, J. R., Devineni, V. R., Janicki, J. S., 1995, “Prevention of

Angiotensin II Induced Myocyte Necrosis and Coronary Vascular Damage by

Lisinopril and Losartan in the Rat,” Cardiovascular Research., 29, pp. 543-548.

128. Richer, C., Giroux, B., Plouin, P. F., Maarek, B., Giudicelli, J. F., 1984,

“Captopril: Pharmacokinetics, Antihypertensive and Biological Effects in

Hypertensive Patients,” British Journal of Clinical Pharmacology., 17, pp. 243-

250.

129. Atlas, S. A., Case, D. B., Sealey, J. E., Laragh, J. H., McKinstry, D. N., 1979,

“Interruption of the Rennin Angiotensin System in Hypertensive Patients by

Captopril Induces Sustained Reduction in Aldosterone Secretion, Potassium

Retention and Natriuresis,” Hypertension., 1, pp. 274-280.

130. Vogh, B. P., Godma, D. R., 1989, “Effect of Inhibition of Angiotensin Converting

Enzyme and Carbonic Anhydrase on Fluid Production by Ciliary Process, Choroid

Plexus, and Pancreas,” Journal of Ocular Pharmacology., 5, pp. 303-311.

131. Chopra, M., McMurray, J., Stewart, J., Dargie, H. J., Smith, W. E., 1990, “Free

Radical Scavenging: A Potentially Beneficial Action of Thiol Containing

Angiotensin Converting Enzyme Inhibitors,” Biochemistry Society Transactions.,

18, pp. 1184-1185.

132. Bhuyan, K. C., Bhuyan, D. K., Santos, O., Podos, S. M., 1992, “Antioxidant and

Anticataractogenic Effects of Topical Captopril in Diquat Induced Cataract in

Rabbits,” Free Radical Biology and Medicine., 12, pp. 251-261.

133. Mansell P., Reckless, J. P. D., 1991, “Garlic: Effects on Serum Lipids, Blood

Pressure, Coagulation, Platelet Aggregation, and Vasodilation,” British Medical

Journal., 303, pp. 379-380.

134. Dausch, J. G., Nixon, D.W., 1990, “Garlic: A Review of its Relationship to

Malignant Disease,” Preventive Medicine., 19, pp. 346-361.

161

135. Hirsch, K., Danilenko, M., Giat, J., 2000, “Effect of Purified Allicin, the Major

Ingredient of Freshly Crushed Garlic, on Cancer Cell Proliferation,” Nutrition and

Cancer., 38, pp. 245-254.

136. Elkayam, A., Mirelman, D., Peleg, E., 2003, “The Effects of Allicin on Weight in

Fructose Induced Hyperinsulinemic, Hyperlipidemic, Hypertensive Rats,”

American Journal of Hypertension., 16, pp. 1053-1056.

137. Miron, T., Rabinkov, A., Peleg, E., Rosenthal, T., Mirelman, D., Wilchek, M.,

2004, “Allylmercaptocaptopril: A New Antihypertensive Drug,” American Journal

of Hypertension., 17, pp. 71-73.

138. Baroni, A., Buommino, E., Ruocco, E., Petrazzuolo, M., De Filippis, A., Satriano,

R. A., Ruocco, V., Cozza, V., Tufano, M. A., 2011, “Captopril Modulates

Acetylcholinesterase in Human Keratinocytes,” Archives of Dermatological

Research., Article in press.

139. Moulder, J. E., Cohen, E. P., Fish, B. L., 2011, “Captopril and Losartan for

Mitigation of Renal Injury Caused by Single-dose Total-body Irradiation,”

Radiation Research., 175, pp. 29-36.

140. Amirshahrokhi, K., Ghazi-Khansari, M., Mohammadi, A., Farani, K. G., 2010,

“Effect of Captopril on TNF-α and IL-10 in the Livers of Bile Duct Ligated Rats,”

Iranian Journal of Immunology., 7, pp. 247-251.

141. Li, S. L., Chen, X., Zhang, X. W., Wu, T., Ji, Z. Z., 2010, “Protective Effects of

Captopril Against Lung Injury In Rats With Severe Acute Pancreatitis,” Nan Fang

Yi Ke Da Xue Xue Bao., 30, pp. 2742-2745.

142. Saghaei, F., Karimi, I., Jouyban, A., Samini, M., 2010, “Effects of Captopril on the

Cysteamine-induced Duodenal Ulcer in the Rat,” Experimental and Toxicologic

Pathology., Article in press.

143. Asdaq, S. M., Inamdar, M. N., 2010, “Potential of Garlic and its Active

Constituent, S-Allyl Cysteine, as Antihypertensive and Cardioprotective in

Presence of Captopril,” Phytomedicine., 17, pp. 1016-1026.

144. Asdaq, S. M., Inamdar, M. N., 2010, “Pharmacodynamic Interaction of Captopril

with Garlic in Isoproterenol-induced Myocardial Damage in Rat,” Phytotherapy

Research., 24, pp. 720-725.

145. Miguel-Carrasco, J. L., Zambrano, S., Blanca, A. J., Mate, A., Vázquez, C. M.,

2010, “Captopril Reduces Cardiac Inflammatory Markers in Spontaneously

Hypertensive Rats by Inactivation of NF-kB,” Journal of Inflammation (London).,

12, pp. 21.

162

146. Roozbeh, J., Banihashemi, M. A., Ghezlou, M., Afshariani, R., Salari, S., Moini,

M., Sagheb, M. M., 2010, “Captopril and Combination Therapy of Captopril and

Pentoxifylline in Reducing Proteinuria in Diabetic Nephropathy,” Renal Failure.,

32, pp. 172-178.

147. Zdionchenko, V. S., Leksina, K. S., Timofeeva, N., Shekhian, G. G., Bagatyrova,

K. M., Mironova, M. A., 2009, “Effect of Angiotensin Converting Enzyme

Inhibitors on Oxidative Stress, Endothelial Function in Patients with Myocardial

Infarction,” Kardiologiia., 49, pp. 32-37.

148. Li, G. X., Liu, Z. Q., 2009, “Captopril and 6-mercaptopurine: Whose SH possess

Higher Antioxidant Ability?,” European Journal of Medicinal Chemistry., 44, pp.

4841-4847.

149. Toshio, O., Shigehiro, T., Yoshitomo, K., Shunichiro, K., 2008, “Protective Effect

of Captopril and Enaraprilat, Angiotensin-converting Enzyme Inhibitors, on Para-

nonylphenol-induced OH Generation and Dopamine Efflux in Rat Striatum,”

Toxicology., 250, pp. 96-99.

150. Miyazaki, A., Kitaichi, N., Ohgami, K., Iwata, D., Jin, X. H., 2008, “Anti-

inflammatory Effect of Angiotensin Type 1 Receptor Antagonist on Endotoxin-

induced Uveitis in Rats,” Graefes Archive for Clinical and Experimental

Ophthalmology., 246, pp. 747-757.

151. Bucci, M., Roviezzo, F., Brancaleone, V., Di Lorenzo, A., 2008, “ACE-inhibition

Ameliorates Vascular Reactivity and Delays Diabetes Outcome in NOD Mice,”

Vascular Pharmacology., 49, pp. 84-90.

152. Zhang, J. Z., Xi, X., Gao, L., Kern, T. S., 2007, “Captopril Inhibits Capillary

Degeneration in the Early Stages of Diabetic Retinopathy,” Current Eye research.,

32, pp. 883-889.

153. Ostergren J., 2007, “Renin Angiotensin System Blockade in the Prevention of

Diabetes,” Diabetes Research and Clinical Practice., 76S, pp. S13-S21.

154. Pasini, A. F., Garbin, U., Nava, M. C., Stranieri, C., 2007, “Effect of Sulfhydryl

and Non-sulfhydryl Angiotensin-converting Enzyme Inhibitors on Endothelial

Function in Essential Hypertensive Patients,” Americal Journal of Hypertension.,

20, pp. 443-450.

155. Ghazi-Khansari, M., Mohammadi-Bardbori A., 2007, “Captopril Ameliorates

Toxicity Induced by Paraquat in Mitochondria Isolated from the Rat Liver,”

Toxicolology In Vitro., 21, pp. 403-407.

163

156. Kalia, K., Narula, G. D., Kannan, G. M., Flora, S. J. S., 2007, “Effects of

Combined Administration of Captopril and DMSA on Arsenite Induced Oxidative

Stress and Blood and Tissue Arsenic Concentration in Rats,” Compound

Biochemistry and Physiology., 144, pp. 372-379.

157. Fiordaliso, F., Cuccovillo, I., Bianchi, R., Bai, A., 2006, “Cardiovascular

Oxidative Stress is Reduced by an ACE inhibitor in a Rat Model of

Streptozotocin-induced Diabetes,” Life Sciences., 79, pp. 121-129.

158. Rosenkranz, A. C., Heinrich, L., Thomas, B., Reinhard, B., Renate, R., 2006,

“Endothelial Antioxidant Actions Dihydropyridines and Angiotensin Converting

Enzyme Inhibitors,” European Journal of Pharmacology., 592, pp. 55-62.

159. Ilieva, I., Ohgami, K., Xue-Hai, J., Suzuki, Y., Shiratori, K., 2006, “Captopril

Suppresses Inflammation in Endotoxin-induced Uveitis in Rats,” Experimental

Eye Research., 83, pp. 651-657.

160. Mariee, A. D., Al-Shabanah, O., 2006, “Protective Ability and Binding Affinity of

Captopril Towards Serum Albumin in an in vitro Glycation Model of Diabetes

Mellitus,” Journal of Pharmaceutical and Biomedical Analysis., 41, pp. 571-575.

161. Basso, N., Paglia, N., Stella, I., Elena, M. V., De Cavanagh., 2005, “Protective

Effect of the Inhibition of the Renin Angiotensin System on Aging,” Regulatory

Peptides., 128, pp. 247-252.

162. Evangelista, S., Manzini, S., 2005, “Antioxidant and Cardioprotective Properties

of the Sulfhydryl Angiotensin Converting Enzyme Inhibitor Zofenopril,” The

Journal of International Medical Research., 33, pp. 42-54.

163. Leiter, L. A., Lewanczuk, R. Z., 2005, “Of the Rennin Angiotensin System and

Reactive Oxygen Species: Type 2 Diabetes and Angiotensin II Inhibition,”

American Journal of Hypertension., 18, pp. 121-128.

164. Jian-Ping, Z., Hong-Shan, W., Shun-Ai, L., Jing-Jing, G., Qian-Ying, Z., Xiao-

Hong, S., Si-Ping, Z., Zhi-Ying, L., Xin F., Hong-Buo, L., 2004, “Effect of

Enalapril on Acute Liver Injury Induced by CCl4 in Rats and its Anti-oxidative

Function,” World Chinese Journal of Digestology., 12, pp. 2638-2641.

165. Elena, M. V., De Cavanagh, E., Piotrkowski, B., Fraga, C. G., 2004. “Concerted

Action of the Rennin Angiotensin System, Mitochondria, and Antioxidant

Defenses in Aging,” Molecular Aspects of Medicine., 25, pp. 27-36.

166. Napoli, C., Sica, V., De Nigris, F., Pignalosa, O., Condorelli, M., 2004,

“Sulfhydryl Angiotensin Converting Enzyme Inhibition Induces Sustained

164

Reduction of Systemic Oxidative Stress and Improves the Nitric oxide Pathway in

Patients with Essential Hypertension,” American Heart Journal., 148, pp. K1-K7.

167. Yavuz, D., Kucukkaya, B., Haklarb, G., Ersoz, O., Akogluc, E., Akalin, S., 2003,

“Effects of Captopril and Losartan on Lipid Peroxidation, Protein Oxidation and

Nitric oxide Release in Diabetic Rat Kidney,” Prostaglandins, Leukotrienes and

Essential Fatty Acids., 69, pp. 223-227.

168. Zhang, J. Z., Gao, L., Widness, M., Xi, X., Kern, T. S., 2003, “Captopril Inhibits

Glucose Accumulation in Retinal Cells in Diabetes,” Investigative ophthalmology

and Visual Sciences., 44, pp. 4001-4005.

169. Scribner, A. W., Loscalzo, J., Napoli, C., 2003, “The Effect of Angiotensin

Converting Enzyme Inhibition on Endothelial Function and Oxidant Stress,”

European Journal of Pharmacology., 482, pp. 95-99.

170. Cominacini, L., Pasini, A. F., Garbin, U., Evangelista, S., 2002, “Zofenopril

Inhibits the Expression of Adhesion Molecules on Endothelial Cells by Reducing

Reactive Oxygen Species,” American Journal of Hypertention., 15, pp. 891-895.

171. Pradhan, R., Fong, D., March, C., Jack, R., 2002, “Angiotensin Converting

Enzyme Inhibition for the Treatment of Moderate to Severe Diabetic Retinopathy

in Normotensive Type 2 Diabetic Patients: A pilot study,” Journal of Diabetes

Complications., 16, pp. 377-381.

172. Thorpe, S. R., Alderson, N. L., Chachich, M. E., Januszweski, A., 2002, “Role of

Dyslipidemia and AGE/ALE Formation in the Progression of Nephropathy and

Retinopathy in STZ-diabetic Rats,” International Congress Series., 1245, pp. 169-

173.

173. EI-Khatib, A. S., Mansour, M. A., 2001, “Prior Treatment with Captopril

Attenuates Carbon tetrachloride Induced Liver Injury in Mice,” Research

Communication in Molecular Pathology and Pharmacolology., 110, pp. 3-16.

174. De Nigris, F., D‟Armiento, F. P., Somma, P., 2001, “Chronic Treatment with

Sulfhydryl Angiotensin Converting Enzyme Inhibitors Inhibit Susceptibility of

LDL to in vitro Oxidation, Formation of Oxidation Specific Epitopes in the

Arterial Wall, and Atherogenesis in Apolipoprotein E Knockout Mice,”

International Journal of Cardiology., 81, pp. 107-115.

175. Sacco, G., Bigioni, M., Evangelista, S., Goso, C., Manzini, S., Maggi, C. A., 2001,

“Cardioprotective Effects of Zofenopril, A New Angiotensin Converting Enzyme

Inhibitor, on Doxorubicin-induced Cardiotoxicity in the Rat,” European Journal of

Pharmacology., 414, pp. 71-78.

165

176. Azza, A. M., Mansour, M., 2000, “Effects of Captopril on Interleukin-6,

Leukotriene B4, and Oxidative Stress Markers in Serum and Inflammatory

Exudates of Arthritic Rats: Evidence of Anti-inflammatory Activity,”

Toxicolology and Pharmacology., 168, pp. 123-130.

177. Ravati, A., Junker, V., Kouklei, M., Ahlemeyer, B., 1999, “Enalapril and

Moexipril Protect from Free Radical-induced Neuronal Damage in vitro and

Reduce Ischemic Brain Injury in Mice and Rats,” European Journal of

Pharmacology., 373, pp. 21-33.

178. Napoli, C., Cicala, C., D‟Armiento, F. P., 1999, “Beneficial Effects of ACE

Inhibition with Zofenopril on Plaque Formation and Low-density Lipoprotein

Oxidation in Watanabe Heritable Hyperlipidemic Rabbits,” General

Pharmacology., 33, pp. 467-477.

179. Desideri, G., Bellini, C., Bmvi, M. C., Ginliani, E., Santuccl, A., Ferii, C., 1999,

“Comparative Study on Zofenopril, Lisinopril, Enalapril and Captopril Effects on

Endothelin-1 and Nitric oxide Production,” Americal Journal of Hypertension., 12,

pp. D007.

180. Elena, M. V., De Cavanagh, E., Ferder, L., Carrasquedo, F., Scrivo, D., 1999,

“Higher Levels of Antioxidant Defenses in Enalapril-treated versus Non-

Enalapril-treated Hemodialysis Patients,” Americal Journal of Kidney Diseases.,

34, pp. 445-455.

181. Neal, R., Cooper, K., Kellogg, G., Gurer, H., Ercal, N., 1999, “Effects of Some

Sulfur-containing Antioxidants on Lead-exposed Lenses,” Free Radical Biology

and Medicine., 26, pp. 239-243.

182. Benzie, F., Tomlinson B., 1998, “Antioxidant Power of ACE Inhibitor in vitro,”

British Journal of Clinical Pharmacology., 45, pp. 168-169.

183. Chaturvedi, N., Sjolie, A., Stephenson, J. M., Abrahamian, H., Keipes, M., 1998,

“Effect of Lisinopril on Progression of Retinopathy in Normotensive People with

Type 1 Diabetes,” Lancet., 351, pp. 28-31.

184. Bartosz, M., Kedziora, J., Bartosz, G., 1997, “Antioxidant and Prooxidant

Properties of Captopril and Enalapril,” Free Radical Biology and Medicine., 23,

pp. 729-735.

185. Ottlecz, A., Bensaoula, T., 1996, “Captopril Ameliorates the Decreased Na+,K

+-

ATPase Activity in the Retina of Streptozotocin-induced Diabetic Rats,”

Investigative Ophthalmology and Visual Sciences., 37, pp. 1633-1641.

166

186. Elena, M. V., De Cavanagh, E., Inserra, F., Ferder, L., Romano, L., 1995,

“Superoxide Dismutase and Glutathione Peroxidase Activities are Increased by

Enalapril and Captopril in Mouse Liver,” FEBS Letters., 361, pp. 22-24.

187. Jan Danser, A. H., Derkx, F. H. M., Admiraal, P. J. J., Deinum, J., 1994,

“Angiotensin Levels in the Eye,” Investigative Ophthalmology and Visual

Sciences., 35, pp. 1008-1018.

188. Andreoli, S. P., 1993, “Captopril Scavenges Hydrogen Peroxide and Reduces but

does not Eliminate, Oxidant-induced Cell Injury,” American Journal of

Physiology. Renal Physiolology., 264, pp. 120-127.

189. Al-Harbi, M. M., 1993, “Effect of Captopril on the Cytological and Biochemical

Changes Induced by Adriamycin,” Food Chemistry and Toxicology., 31, pp. 209-

212.

190. Mak, I. T., Freedman, A. M., Dickens, B. F., Weglicki, W. B., 1990, “Protective

Effects of Sulfhydryl-containing Angiotensin Converting Enzyme Inhibitors

Against Free Radical Injury in Endothelial Cells,” Biochemical Pharmacology.,

40, pp. 2169-2175.

191. Xiu-jun, P., Xiu Chen, J., 1989, “Captopril and Ramiprilat Protect Against Free

Radical Injury in Isolated Working Rat Hearts,” Journal of Molecular Cell

Cardiology., 21, pp. 1261-1271.

192. Li, W., Wang, D., Song, G., Zuo, C., Qiao, X., Qin, S., 2010, “The Effect of

Combination Therapy of Allicin and Fenofibrate on High Fat Diet-induced

Vascular Endothelium Dysfunction and Liver Damage in Rats,” Lipids Health

Disease., 14, pp. 131.

193. Kelsey, N. A., Wilkins, H. M., Linseman, D. A., 2010, “Nutraceutical

Antioxidants as Novel Neuroprotective Agents,” Molecules., 15, pp. 7792-7814.

194. Shahsavani, D., Baghshani, H., Alishahi, E., 2010, “Efficacy of Allicin in

Decreasing Lead (Pb) Accumulation in Selected Tissues of Lead-Exposed

Common Carp (Cyprinus carpio),” Biological Trace Element Research., 2010,

Article in press.

195. Siddique, Y. H., Beg, T., Ara, G., Gupta, J., Afzal, M., 2010, “Antigenotoxic

Effect of Allicin Against Estradiol-17beta-induced Genotoxic Damage in Cultured

Mammalian Cells,” Natural Product Research., 24, pp. 1087-1094.

196. Arzanlou, M., Bohlooli, S., 2010, “Inhibition of Streptolysin O by Allicin: An

Active Component of Garlic,” Journal of Medical Microbiology., 59, pp. 1044-

1049.

167

197. Vazquez-Prieto, M. A., Gonzalez, R. E., Renna, N. F., Galmarini, C. R., Miatello,

R. M., 2010, “Aqueous Garlic Extracts Prevent Oxidative Stress and Vascular

Remodeling in an Experimental Model of Metabolic Syndrome,” Journal of

Agricultural Food Chemistry., 58, pp. 6630-6635.

198. Liu, C., Cao, F., Tang, Q. Z., Yan, L., Dong, Y. G., Zhu, L. H., Wang, L., Bian, Z.

Y., Li, H., 2010, “Allicin Protects Against Cardiac Hypertrophy and Fibrosis via

Attenuating Reactive Oxygen Species-dependent Signaling Pathways,” Journal of

Nutrition and Biochemistry., 21, pp. 1238-1250.

199. Miron, T., Listowsky, I., Wilchek, M., 2010, “Reaction Mechanisms of Allicin and

Allyl-mixed Disulfides with Proteins and Small Thiol Molecules,” European

Journal of Medicinal Chemistry., 45, pp. 1912-1918.

200. Wang, L., Song, M., Hang, T. J., Zhang, Z. X., Shen, W. B., Song, Z., Chen, J.,

2009, “Metabonomic Study on the Effects of Allicin on Rats,” Yao Xue Xue Bao.,

44, pp. 1019-1024.

201. Aslani, M. R., Najarnezhad, V., Mohri, M., 2010, “Individual and Combined

Effect of Meso-2,3-dimercaptosuccinic acid and Allicin on Blood and Tissue Lead

Content in Mice,” Planta Medica., 76, pp. 241-244.

202. Horev-Azaria, L., Eliav, S., Izigov, N., Pri-Chen, S., Mirelman, D., Miron, T.,

Rabinkov, A., Wilchek, M., Jacob-Hirsch, J., Amariglio, N., Savion, N., 2009,

“Allicin Up-regulates Cellular Glutathione Level in Vascular Endothelial Cells,”

European Journal of Nutrition., 48, pp. 67-74.

203. Hoskinson, J., Shelat, K., 2009, “The Effect of Allicin on Escharichia coli,”

California State Science Fair, Project Summary 2009.

204. Anoush, M., Eghbal, M. A., Fathiazad, F., Hamzeiy, H., Kouzehkonani, N. S.,

2009, “The Protective Effects of Garlic Extract Against Acetaminophen-induced

Oxidative Stress and Glutathione Depletion,” Pakistan Journal of Biological

Science., 12, pp. 765-771.

205. Najar, N., Aslani, M. R., Balali, M., 2008, “Evaluation of Allicin for the Treatment

of Experimentally Induced Subacute Lead Poisoning in Sheep,” Biological Trace

Elemental Research., 126, pp. 141-147.

206. Fujisawa, H., Suma, K., Origuchi, K., Seki, T., Ariga, T., 2008, “Thermostability

of Allicin Determined by Chemical and Biological Assays,” Bioscience,

Biotechnology and Biochemistry., 72, pp. 2877-2883.

207. Zhang, Y., Yao, H. P., Huang, F. F., Wu, W., Gao, Y., Chen, Z. B., Liang, Z. Y.,

Liang, T. B., 2008, “Allicin, A Major Component of Garlic, Inhibits Apoptosis in

168

Vital Organs in Rats with Trauma or Hemorrhagic Shock,” Critical Care

Medicine., 36, pp. 3226-3232.

208. Su, Q. S., Tian, Y., Zhang, J. G., Zhang, H., 2008, “Effects of Allicin

Supplementation on Plasma Markers of Exercise-induced Muscle Damage, IL-6

and Antioxidant Capacity,” European Journal of Applied Physiology., 103, pp.

275-283.

209. Mahmoud, H. S., Mahmoud, S. S., Baluchnejadmojarad, T., 2007, “Garlic Extract

Reduces Serum Angiotensin Converting Enzyme Activity in Nondiabetic and

Streptozocin Diabetic Rats,” Pathophysiology., 14, pp. 109-112.

210. Antosiewicz, H., Powolyny, A., Singh, S. V., 2007, “Molecular Targets of Cancer

Chemoprevention by Garlic-derived Organosulfides,” Acta Pharmacologica

Sinica., 28, pp. 1355-1364.

211. Takasu, J., Uykimpang, R., Alenor, S. M., Amagase, H., 2006, “Significance of

Garlic and its Constituents in Cancer and Cardiovascular Diseases- Aged Garlic is

a Potential Therapy for Sickle Cell Anemia,” Journal of Nutrition., 136, pp. 803S-

805S.

212. Seong, J. C., Dong, K. R., Suhkneung, P., 2006, “Allicin, A Major Component of

Garlic, Inhibits Apoptosis of Macrophage in a Depleted Nutritional State,” Basic

Nutrition Investigation., 22, pp. 1177-1184.

213. Raymond, B., Siess, M. H., Arnault, I., Jacques, A., Marie France, P., Marie

France, V., 2004, “Comparision of the Chemopreventive Efficacies of Garlic

Preparations with Different Allicin Contents Against Aflatoxin B1

Carcinogenecity in Rats,” Carcinogenesis., 25, pp. 1953-1959.

214. Amitai, E., Mirelman, D., Peleg, E., Wilchek, M., Miron, T., Rabinkov, A.,

Moron, H., Rosenthal, T., 2003, “The Effects of Allicin on Weight in Fructose-

induced Hyperinsulinemic, Hyperlipidemic, Hypertensive Rats.,” American

Journal of Hypertension., 16, pp. 1053-1056.

215. Rahman, K., 2003, “Garlic and Aging: New Insights into an Old Remedy,” Aging

Research Review., 2, pp. 39-56.

216. Cruz, G., 2001, “Synthesis of Allicin and Purification by Solid-Phase Extraction,”

Analytical Biochemistry., 290, pp. 376-378.

217. Miron, T., Rabinkov, A., Mirelman, D., Wilchek, M., Weiner, L., 2000, “The

Mode of Action of Allicin: Its Ready Permeability Through Phospholipid

Membranes may Contribute to its Biological Activity,” Biochemica Biophysica

Acta., 1463, pp. 20-30.

169

218. Yoshida, H., Katsuzaki, H., Ohta, R., Ishikawa, K., Fukuda, H., Fujini, T., Suzuki,

A., 1999, “Antimicrobial Activity of the Thiosulfinates Isolated from Oil-

macerated Garlic Extract,” Basic Biotechnology and Biochemistry., 63, pp. 591-

594.

219. Siegers, C. P., Steffen, B., Robke, A., Pentz, R., 1999, “The Effects of Garlic

Preparations Against Human Tumor Cell Proliferation,” Phytomedicine., 6, pp. 7-

11.

220. Siegers, C. P., Robke, A., Pentz, R., 1999, “Effects of Garlic Preparations on

Superoxide Production by Phorbol Ester Activated Granulocytes,” Phytomedine.,

6, pp. 6-13.

221. Dirsch, V. M., Kiemer, A. K., Wagner, H., Vollmar, A. M., 1998, “Effect of

Allicin and Ajoene, Two Compounds of Garlic, on Inducible Nitric oxide

Synthase,” Atherosclerosis., 139, pp. 333–339.

222. Rabinkov, A., Miron, T., Konstantinovski, L., Wilchek, M., Mirelman, D., Weiner,

L., 1998, “The Mode of Action of Allicin: Trapping of Radicals and Interaction

with Thiol-containing Proteins,” Biochimica et Biophysica Acta., 1379, pp. 233-

244.

223. Ankri, S., Miron, T., Rabinkov, A., Wilchek, M., Mirelman, D., 1997, “Allicin

from Garlic Strongly Inhibits Cysteine Proteinases and Cytopathic Effects of

Entamoeba histolytica,” Antimicrobial Agents and Chemotherapy., 41, pp. 2286-

2288.

224. Gebhardt, R., Beck, H., 1996, “Differential Inhibitory Effects of Garlic Derived

Organosulfur Compounds on Cholesterol Biosynthesis in Primary Rat Hepatocyte

Cultures,” Lipids., 31, pp. 1269-1276.

225. Mikhin, V. P., Gromnatskii, N. I., 1996, “The Effect of Garlic Preparation on the

Level of Lipid Peroxidation Products, Activity of Various Antioxidant Enzymes,

and Blood Level of Lipoproteins in Patients with Atheroscelrosis,” Biulletene

Eskeperimental Noi Biologii Medistiny., 122, pp. 502-504.

226. Jaiswal, S. K., Bordia, A., 1996, “Radioprotective Effect of Garlic (Allium

sativum, Linn.) in albino rats,” Indian Journal of Medical Sciences., 50, pp. 231-

233.

227. Chu, T. C., Ogidiben, M., Han, J. C., Potter, D. E., 1993, “Allicin-induced

Hypotension in Rabbits,” Journal of Ocular Pharmacology., 9, pp. 201-109.

228. Zhang, R. S., 1992, “A Clinical Study on Allicin in the Prevention of Thrush in

Newborn Infants,” Zhongguo Zhong Xi Yi Jie He Za Zhi., 12, pp. 28-29.

170

229. Gebhardt, R., 1991, “Inhibition of Cholesterol Biosynthesis by a Water-soluble

Garlic Extract in Primary Cultures of Rat Hepatocytes,” Arzneimittelforschung.,

41, pp. 800-804.

230. Focke, M., Feld, A., Lichtenthaler, K., 1990, “Allicin, A Naturally Occurring

Antibiotic from Garlic, Specifically Inhibits Acetyl-CoA Synthetase,” FEBS

Letters., 261, pp. 106-108.

231. Shalinsky, D. R., McNamara, D. B., Agrawal, K. C., 1989, “Inhibition of GSH-

dependent PGH2 Isomerase in Mammary Adenocarcinoma Cells by Allicin,”

Prostaglandins., 37, pp. 135-148.

232. Knasmuller, S., de Martin, R., Domjan, G., Szakmary, A., 1989, “Studies on the

Antimutagenic Activities of Garlic Extract,” Environmental Molecule Mutagen.,

13, pp. 357-365.

233. Mayeux, P. R., Agarwal, J., Tou, H., King, B. T., Lippton, H. L., Hyman, A. L.,

1988, “The Pharmacological Effects of Allicin, A Constituent of Garlic Oil,”

Agents and Actions., 25, pp. 182-190.

234. Younis F., Mirelman, D., Rabinkov, A., Rosenthal, T., 2010, “S-

allylmercaptocaptopril: A Novel Compound in the Treatment of Cohen-Rosenthal

Diabetic Hypertensive Rats,” Journal of Clinical Hypertension (Greenwich)., 12,

pp. 451-455.

235. Ernsberger, P., Janean, L., Rosenthal, T., Mirelman, D., Richard, J. K., 2007,

“Therapeutic Actions of Allylmercaptocaptopril and Captopril in a Rat Model of

Metabolic Syndrome,” American Journal of Hypertension., 20, pp. 866-874.

236. Oron-Herman, M., Rosenthal, T., Mirelman, D., Miron, T., Rabinkov, A.,

Wilchek, M., 2005, “The Effect of S-allylmercaptocaptopril, the Synthetic Product

of Allicin and Captopril, on Cardiovascular Risk Factors Associated with the

Metabolic Syndrome,” Atherosclerosis., 183, pp. 238-243.

237. Devamanoharan, P. S., Henein, M., Ali, A. H., Varma, S. D., 1999, “Attenuation

of Sugar Cataract by Ethyl pyruvate,” Moleclar Cell Biochemistry., 200, pp. 103-

109.

238. Yagci, R., Aydin, B., Erdurmus, M., Karadag, R., Gurel, A., Durmus, M., 2006,

“Use of Melatonin to Prevent Selenite-induced Cataract Formation in Rat Eyes,”

Current Eye Research., 31, pp. 845-850.

239. Shearer, T. R., Ma, H., Fukiage, C., Azuma, M., 1997, “Selenite Nuclear Cataract:

Review of the Model,” Molecular Vision., 3, pp. 8.

171

240. HOPE Investigators., 2000, “Effects of Ramipril on Cardiovascular and

Microvascular Outcomes in People with Diabetes Mellitus: Results of the HOPE

Study and MicroHOPE Substudy,” Lancet., 355, pp. 253-259.

241. Parving, H. H., Lehnert, H., Brochner-Mortensen, J., Gomis, R., Andersen, S.,

Arner, P., 2001, “Irbersartan in Patients with Type 2 Diabetes and

Microalbuminuria Study Group, The Effect or Irbersartan on the Development of

Diabetic Nephropathy in Patients with Type 2 Diabetes,” National England

Journal of Medicine., 345, pp. 870-878.

242. Park, J. B., Intengan, H. D., Schiffrin, E. L., 2000, “Reduction of Resistance

Artery Stiffness by Treatment with the AT1-receptor Antagonist Losartan in

Essential Hypertension,” Journal of Renin Angiotensin Aldosterons System., 1,

pp. 40-45.

243. De Cavanagh, E., Inserra, F., Ferder, L., Fraga, C., 2000, “Enalapril and Captopril

Enhance Glutathione-dependent Antioxidant Defenses in Mouse Tissues,”

American Journal of Physiology., 278, pp. R572-R577.

244. Kukreja, R. C., Kontos, H. A., Hess, M. L., 1990, “Captopril and Enalaprilat do

not Scavenge the Superoxide Anion,” American Journal of Cardiology., 65, pp.

24I-27I.

245. Mira, M. L., Silva, M. M., Queiroz, M. J., Manso, C. F., 1993, “Angiotensin

Converting Enzyme Inhibitors as Oxygen Free Radical Scavengers,” Free Radical

Research Communication., 19, pp. 173-181.

246. Chopra, M., Beswick, H., Clapperton, M., Dargie, H. J, Smith, W.E., McMurray,

J., 1992, “Antioxidant Effects of Angiotensin Converting Enzyme (ACE)

Inhibitors: Free Radical and Oxidant Scavenging are Sulfhydryl Dependent, but

Lipid Peroxidation is Inhibited by both Sulfhydryl- and Nonsulfhydryl Containing

ACE Inhibitors,” Cardiovascular Pharmacology., 19, pp. 330-340.

247. Ghazi-Khansari, M., Nasiri, G., Honarjoo, M., 2005, “Decreasing the Oxidant

Stress from Paraquat in Isolated Perfused Rat Lung Using Captopril and Niacin,”

Archives of Toxicology., 79, pp. 341-345.

248. Ostadalova, I., Babicky, A., Obenberger, J., 1978, “Cataract Induced by

Administration of a Single Dose of Sodium Selenite to Suckling Rats,”

Experientia., 34, pp. 222-223.

249. Ghazi-Khansari, M., Mohammadi-Bardbori, A., 2007, “Non-thiol ACE Inhibitors,

Enalapril and Lisinopril are Unable to Protect Mitochondrial Toxicity due to

Paraquat,” Pesticide Biochemistry Physiology., 89, pp. 163-167.

172

250. Moron, M. S., Depierre, J. W., Mannervik, B., 1979, “Levels of Glutathione,

Glutathione Reductase and Glutathione S-transferase Activities in Rat Lung and

Liver,” Biochimica et Biophysica Acta., 82, pp. 67.

251. Ohkawa, H., Ohishi, N., Yagi, K., 1979, “Assay of Lipid Peroxide in Animal

Tissue by Thiobarbituric Acid Reaction,” Analytical Biochemistry., 95, pp. 351.

252. Lowry, O. H., Rosebrough, N. J., Farr, A. I., 1951, “Protein Measurement with the

Folin Phenol Reagent,” Journal of Biological Chemistry., 193, pp. 265.

253. Shearer, T. R., Anderson, R. S., Britton, J. L., Palmer, E. A., 1983, “Early

Development of Selenium-induced Cataract: Slit Lamp Evaluation,” Experimental

Eye Research., 36, pp. 781-788.

254. Chylack, L. T., Kinashita, J. H., 1969, “A Biochemical Evaluation of a Cataract

Induced in a High Glucose Medium,” Investigative Ophthalmology., 8, pp. 401-

412.

255. Shinohara, T., Piatigorsky, J., 1977, “Regulation of Protein Synthesis, Intracellular

Electrolytes and Cataract Formation in vitro,” Nature., 270, pp. 406-411.

256. Noda, Y., Mori, A., Packer, L., 1997, “Free Radical Scavenging Properties of

Alacepril Metabolites and Lisinopril,” Research Communications in Molecular

Pathology and Pharmacology., 96, pp. 125-136.

257. Al-Shabanad, O., Mansour, M., El-Khasef, H., Al-Bekairi, A., 1998, “Captopril

Ameliorates Myocardial and Haematological Toxicities Induced by Adriamycin,”

Biochemistry and Molecular Biology International., 45, pp. 419-427.

258. Aruoma, O., Akanumu, D., Cecchini, R., Hariwell, B., 1991, “Evaluation of the

Ability of the Angiotensin Converting Enzyme Inhibitor Captopril to Scavenge

Reactive Oxygen Species,” Chemico-biological Interactions., 77, pp. 303-314.

259. Bartosz, M., Kedziora, J., Bartosz, G., “Antioxidant and Pro-oxidant Properties of

Captopril and Enalapril,” Free Radical Biology and Medicine., 23, pp. 29-35.

260. Benzie, I., Tomlison, B., 1998, “Antioxidant Power of Angiotensin Converting

Enzyme Inhibitors in vitro,” British Journal of Clinical Pharmacology., 45, pp.

168-169.

261. Gillis, C. N., Chen, X., Merker, M. M. 1992, “Lisinopril and Ramiprilat Protection

of the Vascular Endothelium Against Free Radical-induced Functional Injury,”

Journal of Pharmacology and Experimental Therapeutics., 262, pp. 212-216.

173

262. Hayek, T., Attias, J., Breslow, J. L., Keidar, S., 1998, “Antiatherosclerotic and

Antioxidative Effects of Captopril in Apolipoprotein-E-deficient Mice,” Journal of

Cardiovascular Pharmacology., 31, pp. 540-544.

263. Ruiz-Munoz, L. M., Vidal-Vanaclocha, F., Lampreabe, I., 1997, “Enalaprilat

Inhibits Hydrogen Peroxide Production by Murine Mesangial Cells Exposed to

High Glucose Concentrations,” Nephrology, Dialysis, Transplantation., 12, pp.

456-464.

264. Elena, M. V., De Cavanagh E. M., Inserra, F., Ferder, L., Fraga, C. G., 2000,

“Enalapril and Captopril Enhance Glutathione-dependent Antioxidant Defenses in

Mouse Tissues,” American Journal of Physiology. Regulatory, Integrative and

Comparative Physiology., 278, pp. 572-577.

265. Rorive, G., Kleinzeller, A., 1974, “Ca2+

-activated ATPase from Renal Tubular

Cells,” Methods of Enzymology., 1974; 32, pp. 303-306.

266. Mishra, H. P., Fridovich, I., 1976, “The Oxidation of Phenylhydrazine: Superoxide

and Mechanism,” Biochemistry., 15, pp. 681-687.

267. Aebi, H., 1974, “Catalase” In: Bergmeyer, H. E., editors. “Methods of Enzymatic

Analysis,” Vol 2, 1st edition, Academic Press, London, pp. 673-677.

268. Paglia, D. E., Valentine, W. N., 1967, “Studies on the Quantitative and Qualitative

Characterization of Erythrocyte Glutathione Peroxidase,” Journal of Laboratory

and Clinical Medicine., 70, pp. 158-159.

269. Hebig, H., 1974, “Gultathione S-tranferase, The First Enzymatic Step in

Mercapturic Acid Formation,” Journal of Biochemistry., 249, pp. 7130-7134.

270. Wride, M. A., 1996, “Cellular and Molecular Features of Lens Differentiation: A

Review of Recent Advances,” Differentiation., 61, pp. 77-93.

271. Galvan, A., Louis, C. F., 1988, “Calcium Regulation by Lens Plasma Membrane

Vesicles,” Archives of Biochemistry and Biophysics., 264, pp. 472-481.

272. Gupta, P. D., Johar, K., Vasavada, A., 2004, “Causative and Preventive Action of

Calcium in Cataractogenesis,” Acta Pharmacologica Sinica., 25, pp. 1250-1256.

273. Liu, L., Paterson, C. A., Borchman, D., 2002, “Regulation of Sarco/endoplasmic

Ca2+

-ATPase Expression by Calcium in Human Lens Cells,” Experimental Eye

Research., 75, pp. 583-590.

174

274. McCord, J. M., Fridovich, I., 1969, “Superoxide Dismutase. An Enzymatic

Function for Erythrocuprein (Hemocuprein),” Journal of Biological Chemistry.,

244, pp. 6049-6055.

275. Varma, S., Ets, T., Richards, R. D., 1977. “Protection Against Superoxide Radicals

in Rat Lens,” Ophthalmic Research., 9, pp. 421-431.

276. Pirie, A., 1965, “Glutathione Peroxidase in Lens and a Source of Hydrogen

Peroxide in Aqueous Humour,” Biochemistry Journal., 96, pp. 244-253.

277. Russell, P., Yamada, T., Xu, G. T., Garland, D., Zigler, J. S., 1991, “Effects of

Naphthalene Metabolites on Cultured Cells from Eye Lens,” Free Radical

Biology and Medicine., 10, pp. 255-261.

278. Bhuyan, K. C., Bhuyan, D. K., 1970, “Catalase in Ocular Tissue and its

Intracellular Distribution in Corneal Epithelium,” American Journal of

Ophthalmology., 69, pp. 147-153.

279. Santini, S. A., Marra, G., Giardina, B., Cotroneo, P., Manto, A., Ghirlanda, A.,

1997, “Defective Plasma Antioxidant Defenses and Enhanced Susceptibility to

Lipid Peroxidation in Uncomplicated IDDM,” Diabetes., 46, pp. 1853-1858.

280. Torok, B., Belagyi, J., Rietz, B. R., 1994, “Effectiveness of Garlic on the Radical

Activity in Radical Generating Systems,” Arzneimittelforschung., 44, pp. 608-611.

281. Stoll, A., Seebeck, E., 1948, “Die Synthese Des Naturlichen Alliins und Seiner

Drei Optisch Aktiven Isomerasen,” Helvetica Chimica Acta., 31, pp. 189-210.

282. Elkayam, A., Mirelman, D., Peleg, E., 2001, “The Effect of Allicin and Enalapril

in Fructose Induced Hyperinsulinemic, Hyperlipidemic, Hypertensive Rats,”

Journal of Hypertension., 14, pp. 377-381.

283. Ali, M., Al-Qattan, K., Al-Enzi, F., 2000, “Effects of Allicin from Garlic Powder

on Serum Lipids and Blood Pressure in Rats Fed with High Cholesterol Diet,”

Prostaglandins, Leukotrienes and Essential Fatty Acids., 64, pp. 253-259.

284. Efendy, J. L., Simmons, D. L., Campbell, G. R., 1997, “The Effect of the Aged

Garlic Extract, “Kiolic”, On the Development of Experimental Atherosclerosis,”

Atherosclerosis., 132, pp. 37-42.

285. Lawson, L. D., Hughes, B. G., 1992, “Inhibition of Whole Platelet Aggregation by

Compounds in Garlic Clove Extracts and Commercial Products,” Thrombosis

Research., 65, pp. 141-156.

175

286. Taylor, A., Hobbs, M., 2001, “2001 Assessment of Nutritional Influences on Risk

of Cataract,” Nutrition., 17, pp. 845-857.

287. Berlett, B. S., Stadtman, E. R., 1997, “Protein Oxidation in Aging, Disease, and

Oxidative Stress,” Journal of Biological Chemistry., 272, pp. 20313-20316.

288. Donma, O., Yorulmaz, E., Pekel, H., Suyugul, N., 2002, “Blood and Lens Lipid

Peroxidation and Antioxidant Status in Normal Individuals, Senile and Diabetic

Cataractous Patients,” Current Eye Research., 25, pp. 9-16.

289. Ozmen, B., Ozmen, D., Erkin, E., Guner, I., Habif, S., Bayindir, O., 2002, “Lens

Superoxide Dismutase and Catalase Activities in Diabetic Cataract,” Clinical

Biochemistry., 35, pp. 69-82.

290. Ates, N. A., Yildirim, O., Tamer, L., Unlu, A., Ercan, B., Muslu, N., 2004,

“Plasma Catalase Activity and Malondialdehyde Level in Patients with Cataract,”

Eye., 18, pp. 785-788.

291. Hashim, Z., Zarina, S., 2006, “Antioxidant Markers in Human Senile and Diabetic

Cataractous Lenses,” Journal of the College of Physicians and Surgeons Pakistan.,

16, pp. 637-640.

292. Canales, A., Sanchez-Muniz, F. J., 2003, “Paraoxonase, Something More than an

Enzyme,” Medicina Clinica., 121, pp. 537-548.

293. Aviram, M., Rosenblat, M., Bisgaier, C. L., Newton, R. S., Primo-Parmo, S. L., La

Du, B. N., 1998, “Paraoxonase Inhibits High-density Lipoprotein Oxidation and

Preserves its Functions: A Possible Peroxidative Role for Paraoxonase,” Journal of

Clinical Investigation., 101, pp. 1581-1590.

294. Watson, A. D., Berliner, J. A., Hama, S. Y., 1995, “Protective Effect of High

Density Lipoprotein Associated Paraoxonase: Inhibition of the Biological Activity

of Minimally Oxidized Low Density Lipoprotein,” Journal of Clinical

Investigation., 96, pp. 2882-2891.

295. Aviram, M., Rosenblatt, M., Billecke, S., 1999, “Human Serum Paraoxonase

(PON1) is Inactivated by Oxidized Low Density Lipoprotein and Preserved by

Antioxidants,” Free Radical Biology and Medicine., 26, pp. 892-904.

296. Jakubowski, H., 2000, “Calcium-dependent Human Serum Homocysteine

Thiolactone Hydrolase: A Protective Mechanism Against Protein N-

Homocysteinylation,” Journal of Biological Chemistry., 275, pp. 3957-3962.

176

297. Josse, D., Lockridge, O., Xie, W., Bartels, C. F., Schopfer, L. M., Masson, P.,

2001, “The Active Site of Human Paraoxonase (PON1),” Journal of Applied

Toxicology., 21, pp. S7-S11.

298. McElveen, J., Mackness, M. I., Colley, C. M., Peard, T., Warner, S., Walker C. H.,

1986, “Distribution of Paraoxon Hydrolytic Activity in the Serum of Patients After

Myocardial Infarction,” Clinical Chemistry., 32, pp. 671-673.

299. Navab, M., Hama-Levy, S., Van-Lenten, B. J., Fonarow, G. C., Cardinez, C. J.,

Castellani, L. W., 1997, “Mildly Oxidized LDL Induces an Increased

Apolipoprotein J/Paraoxonase Ratio,” Journal of Clinical Investigation., 99, pp.

2005-2019.

300. Abbott, C. A., Mackness, M. I., Kumar, S., Boulton, A. J., Durrington, P. N., 1995,

“Serum Paraoxonase Activity, Concentration and Phenotype Distribution in

Diabetes Mellitus and its Relationship to Serum Lipids and Lipoproteins,”

Arteriosclerosis, Thrombosis and Vascular Biology., 15, pp. 1812-1818.

301. Mackness, B., Mackness, M. I., Arrol, S., Turkie, W., Julier, K., Abuasha, B.,

1998. “Serum Paraoxonase (PON1) 55 and 192 Polymorphism and Paraoxonase

Activity and Concentration in Non-insulin Dependent Diabetes Mellitus,”

Atherosclerosis., 139, pp. 341-349.

302. Sakai, T., Matsuura, B., Onji, M., 1998, “Serum Paraoxonase Activity and

Genotype Distribution in Japanese Patients with Diabetes Mellitus,” Internal

Medicine., 37, pp. 581-584.

303. Dantoine, T. F., Debord, J., Charmes, J. P., Merle, L., Marquet, P., Lachatre, G.,

1998, “Decrease of Serum Paraoxonase Activity in Chronic Renal Failure,”

Journal of the American Society of Nephrology., 9, pp. 2082-2088.

304. Baskol, G., Demir, H., Baskol, M., Kilic, E., Ates, F., Kocer, D., 2005,

”Assessment of Paraoxonase 1 Activity and Malondialdehyde Levels in Patients

with Rheumatoid Arthritis,” Clinical Biochemistry., 38, pp. 951-955.

305. Raiszadeh, F., Solati, M., Etemadi, A., Azizi, F., 2004, “Serum Paraoxonase

Activity Before and After Treatment of Thyrotoxicosis,” Clinical Endocrinology.,

60, pp. 75-80.

306. Baskol, G., Karakucuk, S., Oner, A. O., Baskol, M., Kocer, D., Mirza, E., 2006,

“Serum Paraoxonase 1 Activity and Lipid Peroxidation Levels in Patients with

Age-related Macular Degeneration,” Ophthalmologica., 220, pp. 12-16.

177

307. Hashim, Z., Zarina, S., 2007, “Assessment of Paraoxonase Activity and Lipid

Peroxidation Levels in Diabetic and Senile Subjects Suffering from Cataract,”

Clinical Biochemistry., 40, pp. 705-709.

308. Erel, O., 2005, “A New Automated Colorimetric Method for Measuring Total

Oxidant Status,” Clinical Biochemistry., 38, pp. 1103-1111.

309. Erel, O., 2004, “A New Automated Method to Measure Total Antioxidant

Response Against Potent Free Radical Reactions,” Clinical Biochemistry., 37, pp.

112-119.

310. Kosecik, M., Erel, O., Sevinc, E., Selek, S., 2005, “Increased Oxidative Stress in

Children Exposed to Passive Smoking,” International Journal of Cardiology., 100,

pp. 61-64.

311. Gan, K. N., Smolen, A., Eckerson, H. W., La Du, B. N., 1991, ”Purification of

Human Serum Paraoxonase/Arylesterase,” Drug Metabolism and Disposition., 19,

pp. 100-106.

312. Halliwel, B., 2001, “Role of Free Radicals in the Neurodegenerative Diseases:

Therapeutic Implications for Antioxidant Treatment,” Drugs Aging., 18, pp. 685-

716.

313. Vinson, J. A., 2006, “Oxidative Stress in Cataracts,” Pathophysiology., 13, pp.

151-162.

314. Berlett, B. S., Stadtman, E. R., 1997, “Protein Oxidation in Aging, Disease, and

Oxidative Stress,” Journal of Biological Chemistry., 272, pp. 20313-20316.

315. Kregel, K. C., Zhang, H. J., 2007, “An Integrated View of Oxidative Stress in

Aging: Basic Mechanisms, Functional Effects and Pathological Considerations,”

American Journal of Physiology. Regulatory, Integrative and Comparative

Physiology., 292, pp. 18-36.

316. La Du, B. N., 1996. “Structural and Function Diversity of Paraoxonases,” Natural

Medicine., 2, pp. 1186-1187.

317. Mackness, M. I., Mackness, B., Durrington, P. N., Connelly, P. W., Hegele, R. A.,

1996, “Paraoxonase: Biochemistry, Genetics and Relationship to Plasma

Lipoproteins,” Current Opinion in Lipidology., 7, pp. 69-76.

318. Ng, C. J., Wadleigh, D. J., Gangopadhay, A., Hama, S., Grijalva, V., Navab, M.,

2001, “Paraoxonase-2 is a Ubiquitously Expressed Protein with Antioxidant

Properties and is Capable of Preventing Cell-mediated Oxidative Modification of

178

Low Density Lipoprotein,” Journal of Biological Chemistry., 276, pp. 44444-

44449.

319. Berliner, J. A., Navab, M., Fogelman, A. M., Frank, J. S., Demer, L. L., Edwards,

P. A., 1995. “Atherosclerosis: Basic Mechanisms. Oxidation, Inflammation, and

Genetics,” Circulation., 91, pp. 2488-2496.

320. Migdalof, B. H., Antonaccio, M. J., McKinstry, D. N., Singhvi, S. M., Lan, S. J., Egli, P., Kripalani, K J., 1984. “Captopril: Pharmacology, Metabolism and

Disposition,” Drug Metabolism Reviews., 15, pp. 841-869.

321. Orhan, H., Marol, S., Hepsen, I. F., Sahin, G., 1999, “Effects of Some Probable

Antioxidants on Selenite-induced Cataract Formation and Oxidative Stress Related

Parameters in Rats,” Toxicology., 139, pp. 219-232.

322. Babizhayev, M. A., Deyev, A. I., Yermakova, V. N., Brikman, I. V., Bours, J.,

2004, “Lipid Peroxidation and Cataracts: N-acetylcarnosine as a Therapeutic Tool

to Manage Age-related Cataracts in Human and in Canine Eyes,” Drugs in R&D.,

5, pp. 125-139.

323. Fukiage, C., Azuma, M., Nakamura, Y., Tamada, Y., Shearer, T. R., 1998,

“Nuclear Cataract and Light Scattering in Cultured Lenses from Guinea Pig and

Rabbit,” Current Eye Research., 17, pp. 623-635.

324. Tripathi, B. J., Tripathi, R. C., Borisuth, N. S. C., Dhaliwal, R., Dhaliwal, D.,

1991, “Rodent Models of Congenital and Hereditary Cataract in Man,” Lens and

Eye Toxicity Research., 8, pp. 373-413.

325. Augusteyn, R. C., Stevens, A., 1998, “Macromolecular Structure of the Eye Lens,”

Progress in Polymer Science., 23, pp. 375-413.

326. Robertson, L. J., Morton, J. D., Yamaguchi, M., Bickerstaffe, R., Shearer, T. R.,

Azuma, M., 2005, “Calpain may Contribute to Hereditary Cataract Formation in

Sheep,” Investigative Ophthalmology and Visual Sciences., 46, pp. 4634-4640.

327. Lou, M. F., Dickerson, J. E., Jr., Garadi, R., 1990, “The Role of Protein-thiol

Mixed Disulfides in Cataractogenesis,” Experimental Eye Research., 50, pp. 819-

826.

328. Giblin, F. J., McCready, J. P., Schrimscher, L., Reddy, V. N., 1987, “Peroxide-

induced Effect on Lens Cation Transport Following Inhibition of Glutathione

Reductase Activity in vitro,” Experimental Eye Research., 45, pp. 77-91.

179

329. Smith, J. B., Jiang, X., Abraham, E. C., 1997, “Identification of Hydrogen

Peroxide Oxidation Sites of Alpha A- and Alpha B-crystallins,” Free Radical

Research., 26, pp. 103-111.

330. Shang, F., Gong, X., Taylor, A., 1997, “Activity of Ubiquitin-dependent Pathway

in Response to Oxidative Stress,” Journal of Biological Chemistry., 272, pp.

23086- 23093.

331. Li, W. C., Wang, G. M., Wang, R. R., Spector, A., 1994, “The Redox Active

Components H2O2 and N-acetyl-L-cysteine Regulate Expression of c-jun and c-fos

in Lens Systems,” Experimental Eye Research., 59, pp. 179-190.

332. Taylor, A., 1999, “Nutritional and Environmental Influences on Risk for Cataract”

In: Taylor, A., editor. “Nutritional and Environmental Influences on the Eye,”

CRC Press, Boca Raton, FL, pp. 53-93.

333. Szekeres, J., Pacsa, A. S., Pejtsik, B., 1981, “Measurement of Lymphocyte

Cytotoxicity by Assessing Endogenous Alkaline Phosphatase Activity of the

Target Cells,” Journal of Immunological Methods., 40, pp. 151-154.

334. Decker, T., Lohmann-Matthes, M. L., 1988, “A Quick and Simple Method for the

Quantitation of Lactate Dehydrogenase Release in Measurements of Cellular

Cytotoxicity and Tumor Necrosis Factor (TNF) Activity,” Journal of

Immunological Methods., 115, pp. 61-69.

335. Martin, A., Clynes, M., 1991, “Acid Phosphatase: Endpoint for in vitro Toxicity

Tests,” In Vitro Cell Development Biology., 27A, pp. 183-184.

336. David, L. L., Shearer, T. R., 1984, “State of Sulfhydryl in Selenite Cataract,”

Toxicology and Applied Pharmacology., 74, pp. 109-115.

337. Tietze, F., 1969, “Enzymatic Method for Quantitative Determination of Nanogram

Amounts of Total and Oxidised Glutathione: Applications to Mammalian Blood

and Other Tissues,” Analytical Biochemistry., 27, pp. 502-522.

338. Griffith, O. W., 1980, “Determination of Glutathione and Glutathione Disulfide

Using Glutathione Reductase and 2-vinylpyridine,” Analytical Biochemistry., 106,

pp. 207-212.

339. Ramachandran, S., Morris, S. M., Devamanoharan, P., Henein, M., Varma, S. D.,

1991, “Radio-isotopic Determination of Hydrogen Peroxide in Aqueous Humor

and Urine,” Experimental Eye Research., 53, pp. 503-506.

180

340. Giblin, F. J., McCready, J. P., Kodama, T., Reddy, V. N., 1984, “A Direct

Correlation Between the Levels of Ascorbic Acid and H2O2 in Aqueous Humor,”

Experimental Eye Research., 38, pp. 87-93.

341. Spector, A., Garner, W. H., 1981, “Hydrogen Peroxide and Human Cataract,”

Experimental Eye Research., 33, pp. 673-681.

342. Spector, A., Ma, W., Wang, R. R., 1998, “The Aqueous Humor is Capable of

Generating and Degrading H2O2,” Investigative Ophthalmology and Visual

Sciences., 39, pp. 1188-1197.

343. Cornish, K. M., Williamson, G., Sanderson, J., 2002, “Quercetin Metabolism in

the Lens: Role in Inhibition of Hydrogen Peroxide Induced Cataract,” Free

Radical Biology and Medicine., 33, pp. 63-70.

344. Zigler, J. S., Jernigan, H. M., Garland, D., Reddy, V. N., 1985, “The Effects of

"Oxygen Radicals" Generated in the Medium on Lenses in Organ Culture:

Inhibition of Damage by Chelated Iron,” Archives of Biochemistry and

Biophysics., 241, pp. 163-172.

345. Zigler, J. S., Lucas, V. A., Du, X. Y., 1989, “Rhesus Monkey Lens as an in

vitro Model for Studying Oxidative Stress,” Investigative Ophthalmology and

Visual Sciences., 30, pp. 2195-2199.

346. Clements, R. J., Bell, D. S., 1985, “Complications of Diabetes: Prevalence,

Detection, Current Treatment and Prognosis,” American Journal of Medicine., 79,

pp. 2-7.

347. Herman, W. H., Teutsch, S. M., Sepe, S. J., Sinnock, P., Klein, R., 1983, “An

Approach to the Prevention of Blindness in Diabetes,” Diabetes Care., 6, pp. 608-

613.

348. Ramana, B. V., Raju, T. N., Kumar, V. V., Reddy, P. U. M., 2007, “Defensive

Role of Quercetin Against Imbalances of Calcium, Sodium, and Potassium in

Galactosemic Cataract,” Biological Trace Elemental Research., 119, pp. 35-41.

349. Shukla, N., Moitra, J. K., Trivedi, R. C., 1996, “Determination of Lead, Zinc,

Potassium, Calcium, Copper and Sodium in Human Cataract Lenses,” The Science

of Total Environment., 181, pp. 161-165.

350. Saxena, P., Saxena, A. K., Cui, X. L., 2000, “Transition Metal-catalyzed

Oxidation of Ascorbate in Human Cataract Extracts: Possible Role of Advanced

Glycation End Products,” Investigative Ophthalmology and Visual Sciences., 41,

pp. 1473-1481.

181

351. Li-Na, H., Yi-Qun, L., Xiu-Mei, L., 2006, “Puerarin Decreases Lens Epithelium

Cell Apoptosis Induced Partly by Peroxynitrite in Diabetic Rats,” Acta

Physiologica Sinica., 58, pp. 584-592.

352. Kubo, E., Urakami, T., Fatma, N., 2004, “Polyol Pathway-dependent Osmotic and

Oxidative Stresses in Aldose Reductase-mediated Apoptosis in Human Lens

Epithelial Cells: Role of AOP2,” Biochemistry and Biophysics Research

Communication., 314, pp. 1050-1056.

353. Lam, H. C., Lee, J. K., Chiang, H. T., Chuang, M. J., Wang, M. C., 1998, “Is

Captopril Induced Improvement of Insulin Sensitivity Mediated via Endothelin?,”

Journal of Cardiovascular Pharmacology., 31, pp. 496-500.

354. Dal Ponte, D. B., fogt, D. L., Jacob, S., Henriksen, E. J., 1998, “Interactions of

Captopril and Verapamil on Glucose Tolerance and Insulin Action in an Animal

Model of Insulin Resistance,” Metabolism., 47, pp. 982-987.

355. Duarte, J., Martinez, A., Bermejo, A., 1999, “Cardiovascular effects of Captopril

and Enalapril in Obese Zucker Rats,” European Journal of Pharmacology., 365,

pp. 225-232.

356. Swislocki, A. L., Kinney, L. M., Khuu, T. L., Fann, D. T., Tait, K. Y., Rodnick, K.

J., 1999, “Metabolic, Hemodynamic, and Cardiac Effects of Captopril in Young,

Spontaneously Hypertensive Rats,” American Journal of Hypertension., 12, pp.

581-589.

357. Wiggam, M. I., Hunter, S. J., Atkinson, A. B., 1998, “Captopril does not Improve

Insulin Action in Essential Hypertension: A Double-Blind Placebo-Controlled

Study,” Journal of Hypertension., 16, pp. 1651-1657.

358. Naga Raju, T., Kanth Rajani, V., Lavanya, K., 2008, “Effect of Methanolic Extract

of Allium sativum (AS) in Delaying Cataract in STZ-induced Diabetic Rats,”

Journal of Ocular Biology, Diseases and Informatics., 1, pp. 46-54.

359. Follansbee, M. H., Beyer, K. H., Vesell, E. S., 1997, “Studies on

Pyrazinoylguanidine: Prevention of Cataracts in STZ-diabetic Rats,”

Pharmacology., 54, pp. 256-260.

360. West, C. D., Rapoport, S., 1949, “Colorimetric Method for the Estimation of

Dulcitol,” Proceedings of the Social and Experimental Biology., 70, pp. 142-145.

361. Lohr, G. W., Waller, H. D., 1965, “Determination of Glucose-6-phosphate

Dehydrogenase” In: Bergmeyer, H. U., editor. “Methods of Enzymatic Analysis,”

Academic Press, New York, pp. 744-751.

182

362. Beatly, C. M., Basinger, G. M., Dully, C. S., Bocek, R. M., 1966, “Comparison of

Red and White Voluntary Skeletal Muscles of Several Species of Primates,”

Journal of Histochemistry and Cytochemisrty., 14, pp. 590-600.

363. Bergmeyer, H. U., Berht, E., Hess, B., 1965, “Determination of Lactic

Dehydrogenase” In: Bergmeyer, H U., editor. “Methods of Enzymatic Analysis,”

Academic Press, New York, pp. 736-743.

364. Reeves, P. G., 1997, “Components of the AIN-93 Diets as Improvements in the

AIN-76A Diet,” Journal of Nutrition., 127, pp. 838S-841S.

365. Sippel, T. O., 1966, “Changes in the Water, Protein, and Glutathione Contents of

the Lens in the Course of Galactose Cataract Development in Rats,” Investigative

Ophthalmology., 5, pp. 568-575.

366. Van Heyningen, R., 1959, “Formation of Polyols by the Lens of the Rat with

Sugar Cataract,” Nature., 184, pp. 194.

367. Kinoshita, J. H., 1965, “Cataracts in Galactosemia: The Jonas S. Friedenwald

Memorial Lecture,” Investigative Ophthalmology., 4, pp. 786-799.

368. Van Heyningen R., 1959, “Metabolism of Xylose by the Lens. 2. Rat Lens in vivo

and in vitro,” Biochemistry Journal., 73, pp. 197-107.

369. Hockwin, O., Ohrloff, C., 1979, “Ageing of Lens Metabolism,” Ophthalmic

Research., 11, pp. 389-307.

370. Hockwin, O., Korte, I., 1968, In: Nordmann, J., Dardanne, M. U., editors.

“Biochemistry of the Eye,” S. Karger, Basel, pp. 216-221.

371. Rawal, U. M., Rao, G. M., 1980, “Enzymatic Studies on the Galactose Exposed

Lens,” Indian Journal of ophthalmology., 28, pp. 5-7.

372. Iwig, M., Glasser, D., Hieka, H., 1978, “Reactivation of Nucleus Containing Lens

Fibre Cells to Mitotic Growth Biochemical and Immunochemical Analysis,” Cell

Differentiation., 7, pp. 159-169.

373. Iwig, M., Glasser, D., 1972, “Investigations on Mitotic Activity, Cell Density, and

Enzyme Activities in the Bovine Eye during Cell Differentiation,” Ophthalmic

Research., 4, pp. 328-342.

374. Magaw, J. M., 1984. “Glutathione and Ocular Photobiology,” Current Eye

Research., 3, pp. 83-87.

APPENDIX 1